SCHEMBL675930

SCHEMBL675930

COc1ccc2c(c1OC)C(=O)OC2c1cccc2cnccc12

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.46
ALDH1A1 P00352 7/20 0.46
KMT2A Q03164 7/20 0.46
TAAR1 Q96RJ0 1/20 0.46
HTT P42858 3/20 0.45
HSD17B10 Q99714 1/20 0.45
MAPT P10636 9/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
HPGD P15428 3/20 0.45
CYP2C19 P33261 1/20 0.44
PDE10A Q9Y233 1/20 0.43
POLB P06746 2/20 0.42
HIF1A Q16665 1/20 0.42
GAA P10253 1/20 0.42
NPSR1 Q6W5P4 3/20 0.41
LMNA P02545 1/20 0.41
NPC1 O15118 1/20 0.40
PLA2G1B P04054 1/20 0.40
NFKB1 P19838 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2044959 0.76 PDE10A (0.38) KDM4EALDH1A1MAPTSMN1; SMN2CYP2C19
SCHEMBL675941 0.74 ALDH1A1 (0.47) KDM4EALDH1A1HTTMAPTHPGD
SCHEMBL9828002 0.70 MAOA (0.53) KDM4EALDH1A1HSD17B10MAPTSMN1; SMN2
SCHEMBL28013610 0.69 MAOA (0.47) KDM4EALDH1A1HTTMAPTSMN1; SMN2
SCHEMBL96459 0.68 MAPT (0.58) KDM4EALDH1A1HTTMAPTSMN1; SMN2
SCHEMBL10689948 0.66 MAPT (0.50) KDM4EALDH1A1KMT2ATAAR1HTT
SCHEMBL2974564 0.65 ALDH1A1 (0.60) KDM4EALDH1A1KMT2AHTTMAPT
SCHEMBL10686775 0.65 KDM4E (0.49) KDM4EALDH1A1KMT2ATAAR1HTT
SCHEMBL10686771 0.65 MAPT (0.52) KDM4EALDH1A1KMT2ATAAR1HTT
SCHEMBL14970288 0.65 KDM4E (0.73) KDM4EALDH1A1KMT2ATAAR1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110274651-A1 Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition EMORY UNIVERSITY (US) 2011-11-10 US disclosed
EP-2328578-A2 NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION Emory University (US) 2011-06-08 EP disclosed
WO-2010030582-A2 NOSCAPINE AND NOSCAPINE ANALOGS AND THEIR USE IN TREATING INFECTIOUS DISEASES BY TUBULIN BINDING INHIBITION EMORY UNIVERSITY (US) 2010-03-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110274651-A1 Noscapine and Noscapine Analogs and Their Use in treating Infectious Diseases by Tubulin Binding Inhibition NOS1, NOS2, TBCA KDM4E 4136/4885ALDH1A1 4538/4885KMT2A 4357/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.